BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech ...

BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report that doubled year-over-year revenue to €260.8 million, well above analysts’ ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...

Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and co-commercialize the bispecific antibody BNT327, targeting multiple solid tumor ...

Investing.com -- BioNTech SE (NASDAQ:BNTX) and Bristol Myers (NYSE:BMY) Squibb have announced their global collaboration for the co-development and co-commercialization of BioNTech’s experimental ...

Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment. The pharmaceutical behemoth ...

Bristol-Myers Squibb and BioNTech have entered a collaboration to co-develop and commercialize BioNTech's BNT327, a clinical-stage PD-L1/VEGF-A bispecific antibody for treating cancer.

Bristol Myers Squibb (NYSE: BMY) is paying up to $11.1B in a licensing agreement to help develop BioNTech's (NASDAQ: BNTX) immunotherapy bispecific antibody BNT327 for solid tumors.

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types ...